Humabodies come of age
Crescendo's small Humabodies grow up
With its transgenic mouse platform now in place, a deal with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) in hand and a new CSO announced this week, Crescendo Biologics Ltd. has pivoted from technology optimization to therapeutic development. Having amassed an inventory of different Humabodies, the company is combining them in new ways to build a war chest of modular therapies for immuno-oncology.
Crescendo has disclosed four preclinical compounds targeting tumor antigens or checkpoint molecules, and plans to have up to three programs in the clinic in 2019. ...